FindTrial
Sign In

Study of superficial lynmph nodes whit superparamagnetic contrast and RMN in patient affected by melanoma. - Superparamagnetic contrast in melanoma

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2007-005459-41-IT
Enrollment
Unknown
Registered
2007-11-14
Start date
2007-09-17
Completion date
Unknown
Last updated
2012-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

melanomas of limbs. MedDRA version: 9.1 Level: LLT Classification code 10025650 Term: Malignant melanoma

Interventions

Trade Name: RESOVIST Pharmaceutical Form: Solution for infusion INN or Proposed INN: Iron oxide, nanoparticles Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 756-

Sponsors

AZIENDA OSPEDALIERA DI PADOVA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: ege > 18 years old;diagnosis of melanoma of lower and upper limbs and request of liver stadiation. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: RMN controindication.allergy to mdc; pregress Surgery and radiotherapy in areas.Non collaborant patients.

Design outcomes

Primary

MeasureTime frame
Main Objective: lynph nodes capacity of fixation of superparamagnetic contrast by iniecton S.C. in the area of primary lesion that is distal from lynph nodes examinated.indicationes of recognition potentiality of lynph node lesions.;Secondary Objective: ;Primary end point(s): recognition of lynph node lesions.—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026